VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

ESGCT 2021 | Educating HCPs and patients on novel therapies for metabolic disorders

Mark Thomas, MD, Royal Perth Hospital, Perth, Australia, discusses the importance of education for both healthcare professionals and patients as novel therapeutic products such as gene therapies are developed and being investigated in clinical trials for a range of metabolic disorders. He compares the differences in treatment approaches in kidney transplant patients requiring long-term management and follow-up, compared to patients receiving a single-infusion of AVR-RD-01, an investigational ex vivo lentiviral gene therapy for Fabry disease (FD). Dr Thomas also commends patients who are willing to enrol in early-stage clinical trials evaluating advanced therapies and highlights the economic benefit these trials have at a national level. This interview took place at the European Society of Gene & Cell Therapy (ESGCT) Virtual Congress 2021.